Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study.

Marta VasylyevFerdinand W N M WitCarlijn C E JordansRobin SoetekouwSteven F L van LelyveldGert-Jan KootstraCorine E DelsingHeidi S M AmmerlaanMarjo E E van KasterenAnnemarie E BrouwerEliane M S LeytenMark A A ClaassenRobert-Jan HassingJan G den HollanderMarcel van den BergeAnna H E RoukensWouter F W BiermanPaul H P GroeneveldSelwyn H LoweBerend J van WelzenOlivier RichelJeannine F NellenGuido E L van den BerkMarc van der ValkBart J A RijndersCasper Rokx

Published in: Open forum infectious diseases (2024)

NCT04707326.

Keyphrases

antiretroviral therapy
hiv infected patients
human immunodeficiency virus
hiv infected
hiv positive
hiv aids
emergency department
hepatitis c virus
adverse drug